TABLE 1.
Meningococcal strains used in this study
| Strain | Clonal complex | STa | Yr isolated | Countryb | Serogroup:serotype:serosubtypec | fHbp subvariantc |
|---|---|---|---|---|---|---|
| MC58 | 32 | 74 | 1985 | UK | B:15:P1.7,16b | 1.1 |
| M14879 | 1157 | 1157 | 2006 | USA | B:NA:P1.22,14-6 | 1.13 |
| NZ98/254 | 41/44 | 42 | 1998 | NZ | B:4:P1.4 | 1.14 |
| M01-0240660 | 269 | 269 | 2001 | UK | B:NA:P1.19,15 | 1.15 |
| M08-240104 | 35 | 35 | 2008 | UK | B:4:P1.14 | 2.16 |
| M12566 | 41/44 | 5111 | 2004 | USA | B:4,7:P1.4 | 2.19 |
| M1239 | 41/44 | 437 | 1995 | USA | B:14:P1.23,14 | 3.28 |
| M01-240988 | 213 | 213 | 2001 | UK | B:1:NA | 3.30 |
| M01-240355 | 213 | 213 | 2001 | UK | B:1:NA | 3.31 |
| LNP24551 | 32 | 34 | 2008 | FR | B:4:P1.5,2 | 3.116 |
a
ST, sequence type.
b
NZ, New Zealand; FR, France.
c
The fHbps are named in terms of the translated (protein) sequence, as variant class.protein ID, in accordance with the public fHbp database (http://pubmlst.org/neisseria/fHbp/), in which new protein variants are assigned a sequential numerical identifier, alongside a prefix corresponding to the Novartis variant designation (variant 1, 2, or 3). For example, fHbp 1.1 refers to Novartis subvariant 1, neisseria.org protein subvariant 1. ST, sequence type as determined by MLST. NA, not assigned.